Complicated Urinary Tract Infections - Epidemiology Forecast - 2032

Market Report | 2022-08-01 | 122 pages | DelveInsight

AVAILABLE LICENSES:

- Single User Price $3950.00
- Site License Price $7900.00
- Enterprise Price $11850.00

Report description:

DelveInsight's " Complicated Urinary Tract Infection (cUTI)- Epidemiology Forecast-2032" report delivers an in-depth understanding of the Complicated Urinary Tract Infection, historical and forecasted epidemiology as well as the Complicated Urinary Tract Infection trends in the United States, EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

- The United States
- EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan

Study Period: 2019-2032

Complicated Urinary Tract Infection (cUTI) Understanding

The DelveInsight's Complicated Urinary Tract Infection epidemiology report gives a thorough understanding of Complicated Urinary Tract Infection. Urinary tract infections (UTIs) are amongst the most frequent bacterial infections. They can manifest clinically in various ways, from relatively benign, uncomplicated infections to complicated UTIs (cUTIs), pyelonephritis, and severe urosepsis. cUTI is a heterogeneous entity comprising multiple forms.

Several classification systems exist for the description and classification of UTIs, with the common rationale that cUTIs have a higher risk of recurrence or chronification, progression, or severe outcome than uncomplicated UTIs. High antibiotic resistance rates among the causing bacteria are linked to cUTIs and pyelonephritis.aHUS is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. These clots can cause serious medical problems if they restrict or block blood flow. It is characterized by three major features related to abnormal clotting: hemolytic anemia, thrombocytopenia, and kidney failure.

The colonization of the urogenital tract by rectal and perineal flora is the primary cause of UTIs. Escherichia coli, Enterococcus, Klebsiella, Pseudomonas, and other Enterococcus or Staphylococcus species are among the most prevalent microorganisms; the most frequent of them is Escherichia coli, followed by Klebsiella. Candida can colonize individuals receiving residential care, diabetics, those with indwelling catheters, and people with any type of immune impairment.

Patients prone to infection risks tend to get cUTIs more frequently. The likelihood of a cUTI may be increased by the following: age, particularly that of older people and small children, diabetes, renal illness, cancerous bladder blockage, pregnancy with a

compromised immune system, and an underlying urologic problem that was recently treated with a catheter.
Despite the frequency of UTIs present in hospitals, they (especially cUTIs) continue to be a clinical entity that causes major confusion, diagnostic ambiguity, and a source of large inappropriate antibiotic prescriptions.
The most crucial clinical criteria for the first diagnosis of a UTI are symptoms, such as increased urinary frequency, urgency, hematuria, dysuria, suprapubic or flank discomfort. Additionally, there must be a suitable clinical scenario in which the most likely cause of these symptoms is an infection of the urogenital tract.
First-line antibiotics should be used to begin empiric therapy in this circumstance. Before initiating therapy, a urine sample should be sent for microscopy and culture. Severe cUTIs can present as severe undifferentiated sepsis or even septic shock.
Pharmacotherapy aims to eradicate the infection, prevent complications, and provide symptomatic relief to patients. Early treatment is recommended to reduce the risk of progression to pyelonephritis. The treatment goals are to get rid of the infection, prevent complications, and help provide symptomatic relief. In order to lower the risk of developing pyelonephritis, early treatment is recommended. When considering empirical antimicrobial selection, it is critical to recognize antimicrobial resistance trends. The main course of treatment for individuals with lower UTIs is an oral medication with an empirically selected antibiotic that is effective against Gram-negative aerobic coliform bacteria, such as Escherichia coli. Currently, there are several types of medications used for treatment purposes, namely beta-lactamase inhibitors, protein synthesis inhibitors, and others. At times, combination therapy and dietary supplementation are also prescribed.
Complicated Urinary Tract Infection (cUTI) Epidemiology
The epidemiology section provides insights about the historical and current Complicated Urinary Tract Infection patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides a historical as well as forecasted Complicated Urinary Tract Infection epidemiology scenario in the 7MM covering the United States, EU-5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total diagnosed incident cases of cUTI were 8.08 Million (M) in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Complicated Urinary Tract Infection epidemiology [segmented as Total Diagnosed-incident Cases of Complicated Urinary Tract Infection, Total Age-specific Cases of Complicated Urinary Tract Infection, Total Pathogen-specific Cases of Complicated Urinary Tract Infection, and Total Treated Cases (across lines) of Complicated Urinary Tract Infection] in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.?
Country Wise- Complicated Urinary Tract Infection (cUTI) Epidemiology
The epidemiology segment also provides the Complicated Urinary Tract Infection epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
According to the DelveInsight, in the year 2021, the total diagnosed incident cases of cUTI were 3.43 M in the United States which are expected to grow during the study period, i.e., 2019-2032.
The highest number of total incident cases of cUTI was observed in Germany among the EU5 countries with 0.87 M cases in 2021 which are expected to grow during the study period, i.e., 2019-2032.
In the year 2021, the total diagnosed incident cases of cUTI were 1.28 M in Japan which are expected to grow during the study period, i.e., 2019-2032.
KOL- Views
To keep up with the current Complicated Urinary Tract Infection patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Complicated Urinary Tract Infection domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Scope of the Report

- The report covers the descriptive overview of Complicated Urinary Tract Infection, explaining their causes, symptoms, pathophysiology, and genetic basis.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of Complicated Urinary Tract Infection.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM total diagnosed-incident cases of complicated urinary tract infection, total age-specific cases of complicated urinary tract infection, total pathogen-specific cases of complicated urinary tract infection, and total treated cases (across lines) of complicated urinary tract infection in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Complicated Urinary Tract Infection R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Complicated Urinary Tract Infection.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Complicated Urinary Tract Infection (cUTI) Report Key Strengths

- 11 Years Forecast
- 7MM Coverage
- Complicated Urinary Tract Infection Epidemiology Segmentation

Key Questions

Epidemiology Insights:

- What are the disease risk, burden, and regional/ethnic differences of Complicated Urinary Tract Infection?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU-5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Complicated Urinary Tract Infection patient pool in seven major markets covering the United States, EU-5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Complicated Urinary Tract Infection in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about Complicated Urinary Tract Infection?
- Out of all 7MM countries, which country would have the highest prevalent population of Complicated Urinary Tract Infection during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Reasons to buy

- The report will help in developing business strategies by understanding trends shaping and driving the Complicated Urinary Tract Infection Disease market
- To understand the future market competition in the Complicated Urinary Tract Infection Disease market
- Organize sales and marketing efforts by identifying the best opportunities for Complicated Urinary Tract Infection Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Complicated Urinary Tract Infection Disease

market
- To understand the future market competition in the Complicated Urinary Tract Infection Disease market

Table of Contents:

SCOTTS INTERNATIONAL

Complicated Urinary Tract Infections - Epidemiology Forecast - 2032

Market Report | 2022-08-01 | 122 pages | DelveInsight

To place an Order with Scotts International:

- - Print this form
- - Complete the relevant blank fields and sign
- - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	$3950.00
	Site License Price	$7900.00
	Enterprise Price	$11850.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2025-05-10
		Signature	